Synovial Sarcoma-Pipeline Review, H1 2016

Synovial Sarcoma-Pipeline Review, H1 2016


  • Products Id :- GMDHC7773IDB
  • |
  • Pages: 125
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Synovial Sarcoma-Pipeline Review, H1 2016', provides an overview of the Synovial Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Synovial Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Synovial Sarcoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Synovial Sarcoma

The report reviews pipeline therapeutics for Synovial Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Synovial Sarcoma therapeutics and enlists all their major and minor projects

The report assesses Synovial Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Synovial Sarcoma

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Synovial Sarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Synovial Sarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Synovial Sarcoma Overview 7

Therapeutics Development 8

Pipeline Products for Synovial Sarcoma-Overview 8

Pipeline Products for Synovial Sarcoma-Comparative Analysis 9

Synovial Sarcoma-Therapeutics under Development by Companies 10

Synovial Sarcoma-Therapeutics under Investigation by Universities/Institutes 11

Synovial Sarcoma-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Synovial Sarcoma-Products under Development by Companies 14

Synovial Sarcoma-Products under Investigation by Universities/Institutes 15

Synovial Sarcoma-Companies Involved in Therapeutics Development 16

Adaptimmune Therapeutics Plc 16

Advenchen Laboratories, LLC 17

EpiZyme, Inc. 18

Immune Design Corp. 19

Karyopharm Therapeutics, Inc. 20

Merck & Co., Inc. 21

Novartis AG 22

OncoTherapy Science, Inc. 23

Takara Bio Inc. 24

Synovial Sarcoma-Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

AL-3818-Drug Profile 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

CMB-305-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

everolimus-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

GSK-3377794-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

OTSA-101-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

pembrolizumab-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

selinexor-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

SSTC-104-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

tazemetostat-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

TBI-1301-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Synovial Sarcoma-Recent Pipeline Updates 69

Synovial Sarcoma-Discontinued Products 112

Synovial Sarcoma-Product Development Milestones 113

Featured News & Press Releases 113

Feb 09, 2016: U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune's Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma 113

Feb 02, 2016: Adaptimmune and GSK expand Strategic Immunotherapy Collaboration 113

Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors 114

Nov 05, 2015: Adaptimmune Announces Data From Clinical Study of NY-ESO Affinity Enhanced T-Cell Therapy in Synovial Sarcoma at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer 116

Oct 30, 2015: Adaptimmune To Present new data from NY-ESO at the 2015 Annual Meeting of the Society of Immunotherapy for Cancer 118

Sep 01, 2015: Adaptimmune Expands Trial of T-cell Therapy for Synovial Sarcoma and Achieves Clinical Milestones 118

Aug 24, 2015: Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma 119

May 30, 2015: Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting 121

May 21, 2015: Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting 122

May 13, 2015: Adaptimmune Announces Upcoming Data Presentation at the 2015 Annual American Society of Gene and Cell Therapy (ASGCT) Meeting 123

Appendix 124

Methodology 124

Coverage 124

Secondary Research 124

Primary Research 124

Expert Panel Validation 124

Contact Us 124

Disclaimer 125

List of Figures

Number of Products under Development for Synovial Sarcoma, H1 2016 8

Number of Products under Development for Synovial Sarcoma-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Comparative Analysis by Clinical Stage Development, H1 2016 12

Assessment by Monotherapy Products, H1 2016 25

Number of Products by Top 10 Targets, H1 2016 26

Number of Products by Stage and Top 10 Targets, H1 2016 26

Number of Products by Top 10 Mechanism of Actions, H1 2016 28

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 28

Number of Products by Routes of Administration, H1 2016 30

Number of Products by Stage and Routes of Administration, H1 2016 30

Number of Products by Molecule Types, H1 2016 32

Number of Products by Stage and Molecule Types, H1 2016 32

List of Tables

Number of Products under Development for Synovial Sarcoma, H1 2016 8

Number of Products under Development for Synovial Sarcoma-Comparative Analysis, H1 2016 9

Number of Products under Development by Companies, H1 2016 10

Number of Products under Investigation by Universities/Institutes, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 12

Comparative Analysis by Early Stage Development, H1 2016 13

Products under Development by Companies, H1 2016 14

Products under Investigation by Universities/Institutes, H1 2016 15

Synovial Sarcoma-Pipeline by Adaptimmune Therapeutics Plc, H1 2016 16

Synovial Sarcoma-Pipeline by Advenchen Laboratories, LLC, H1 2016 17

Synovial Sarcoma-Pipeline by EpiZyme, Inc., H1 2016 18

Synovial Sarcoma-Pipeline by Immune Design Corp., H1 2016 19

Synovial Sarcoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2016 20

Synovial Sarcoma-Pipeline by Merck & Co., Inc., H1 2016 21

Synovial Sarcoma-Pipeline by Novartis AG, H1 2016 22

Synovial Sarcoma-Pipeline by OncoTherapy Science, Inc., H1 2016 23

Synovial Sarcoma-Pipeline by Takara Bio Inc., H1 2016 24

Assessment by Monotherapy Products, H1 2016 25

Number of Products by Stage and Target, H1 2016 27

Number of Products by Stage and Mechanism of Action, H1 2016 29

Number of Products by Stage and Route of Administration, H1 2016 31

Number of Products by Stage and Molecule Type, H1 2016 33

Synovial Sarcoma Therapeutics-Recent Pipeline Updates, H1 2016 69

Synovial Sarcoma-Discontinued Products, H1 2016 112

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Adaptimmune Therapeutics Plc

Advenchen Laboratories, LLC

EpiZyme, Inc.

Immune Design Corp.

Karyopharm Therapeutics, Inc.

Merck & Co., Inc.

Novartis AG

OncoTherapy Science, Inc.

Takara Bio Inc.

Synovial Sarcoma Therapeutic Products under Development, Key Players in Synovial Sarcoma Therapeutics, Synovial Sarcoma Pipeline Overview, Synovial Sarcoma Pipeline, Synovial Sarcoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com